DE3043409C2 - - Google Patents
Info
- Publication number
- DE3043409C2 DE3043409C2 DE3043409T DE3043409T DE3043409C2 DE 3043409 C2 DE3043409 C2 DE 3043409C2 DE 3043409 T DE3043409 T DE 3043409T DE 3043409 T DE3043409 T DE 3043409T DE 3043409 C2 DE3043409 C2 DE 3043409C2
- Authority
- DE
- Germany
- Prior art keywords
- heparin
- prothrombin complex
- iii
- prothrombin
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102100027378 Prothrombin Human genes 0.000 claims description 43
- 108010094028 Prothrombin Proteins 0.000 claims description 43
- 229940039716 prothrombin Drugs 0.000 claims description 43
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 32
- 229960002897 heparin Drugs 0.000 claims description 32
- 229920000669 heparin Polymers 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 22
- 238000010828 elution Methods 0.000 claims description 16
- 238000001179 sorption measurement Methods 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 108090000935 Antithrombin III Proteins 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 11
- 102000004411 Antithrombin III Human genes 0.000 claims description 10
- 229960005348 antithrombin iii Drugs 0.000 claims description 10
- 239000003463 adsorbent Substances 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 239000007858 starting material Substances 0.000 claims description 6
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 5
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 102100027827 Complexin-3 Human genes 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 238000007792 addition Methods 0.000 description 10
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229910052593 corundum Inorganic materials 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910001845 yogo sapphire Inorganic materials 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960004222 factor ix Drugs 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000009852 coagulant defect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102100022977 Antithrombin-III Human genes 0.000 description 1
- -1 DEAE-Sephadex Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7911272A FR2472390A1 (fr) | 1979-05-04 | 1979-05-04 | Procede de preparation de concentres de complexe prothrombinique hautement purifies, et concentres obtenus |
| PCT/FR1980/000069 WO1980002426A1 (fr) | 1979-05-04 | 1980-05-05 | Concentres de complexe prothrombinique, preparation et application |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE3043409T1 DE3043409T1 (de) | 1982-02-18 |
| DE3043409C2 true DE3043409C2 (en, 2012) | 1993-12-23 |
| DE3043409C3 DE3043409C3 (de) | 1993-12-23 |
Family
ID=9225039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3043409T Expired - Fee Related DE3043409C3 (de) | 1979-05-04 | 1980-05-05 | Verfahren zur Herstellung eines Konzentrats eines Prothrombin-Komplexes |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4465623A (en, 2012) |
| JP (1) | JPH0424360B2 (en, 2012) |
| AR (1) | AR227021A1 (en, 2012) |
| AT (1) | ATA903980A (en, 2012) |
| BE (1) | BE883096A (en, 2012) |
| CA (1) | CA1157375A (en, 2012) |
| CH (1) | CH654329A5 (en, 2012) |
| DE (1) | DE3043409C3 (en, 2012) |
| DK (1) | DK157169C (en, 2012) |
| ES (1) | ES491042A0 (en, 2012) |
| FR (1) | FR2472390A1 (en, 2012) |
| GB (1) | GB2061287B (en, 2012) |
| IT (1) | IT1131109B (en, 2012) |
| MX (1) | MX5960E (en, 2012) |
| NL (1) | NL8020152A (en, 2012) |
| NO (1) | NO155477C (en, 2012) |
| SE (1) | SE452250C (en, 2012) |
| WO (1) | WO1980002426A1 (en, 2012) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0044343B1 (en) * | 1980-01-28 | 1984-08-22 | Baxter Travenol Laboratories, Inc. | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
| US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
| AT379310B (de) * | 1983-05-20 | 1985-12-27 | Immuno Ag | Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates |
| US4786726A (en) * | 1986-01-06 | 1988-11-22 | Blood Systems, Inc. | Factor IX therapeutic blood product, means and methods of preparing same |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
| DE3625090A1 (de) * | 1986-07-24 | 1988-01-28 | Behringwerke Ag | Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung |
| DE3727610A1 (de) * | 1987-08-19 | 1989-03-02 | Behringwerke Ag | Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung |
| US6541275B1 (en) | 1988-02-03 | 2003-04-01 | Dade Behring Inc. | Immunoassay for F1.2 prothrombin fragment |
| JPH0219400A (ja) * | 1988-07-07 | 1990-01-23 | Green Cross Corp:The | トロンビンまたはプロトロンビンの製造方法 |
| KR100330540B1 (ko) * | 1993-04-05 | 2002-09-04 | 웰파이드 코포레이션 | 안티트롬빈-iii액상제제및그안정화방법 |
| US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
| US6491965B1 (en) | 1995-11-30 | 2002-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US6562781B1 (en) | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US20080306610A1 (en) * | 2007-06-07 | 2008-12-11 | Zimmer Orthobiologics, Inc. | Tissue processing for nonimmunogenic implants |
| US8435305B2 (en) | 2010-08-31 | 2013-05-07 | Zimmer, Inc. | Osteochondral graft delivery device and uses thereof |
| USD843660S1 (en) | 2017-11-27 | 2019-03-19 | Mary Kay Inc. | Cosmetic compact |
| USD863685S1 (en) | 2017-11-27 | 2019-10-15 | Mary Kay Inc. | Cosmetic compact |
| USD850006S1 (en) | 2017-11-27 | 2019-05-28 | Mary Kay Inc. | Cosmetic compact |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560475A (en) * | 1969-06-19 | 1971-02-02 | Baxter Laboratories Inc | Prothrombin complex prepared by precipitation with polyethylene glycol |
| EP0018353A1 (de) * | 1979-04-19 | 1980-10-29 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Verfahren zur Herstellung von nebenwirkungsfreien Plasmafraktionen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2867567A (en) * | 1955-01-21 | 1959-01-06 | Nat Res Dev | Process of preparing anti-haemophilic globulin |
| JPS5314604B2 (en, 2012) * | 1972-12-20 | 1978-05-18 | ||
| US4087415A (en) * | 1976-06-09 | 1978-05-02 | William L. Wilson | Antithrombin III |
| US4081432A (en) * | 1977-07-25 | 1978-03-28 | Monsanto Company | Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers |
| JPS6040859B2 (ja) * | 1977-07-27 | 1985-09-12 | 喜温 三浦 | 抗血栓性人工医療材料 |
| DE3101752A1 (de) * | 1981-01-21 | 1982-08-26 | Behringwerke Ag, 3550 Marburg | "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen" |
-
1979
- 1979-05-04 FR FR7911272A patent/FR2472390A1/fr active Granted
-
1980
- 1980-04-30 ES ES491042A patent/ES491042A0/es active Granted
- 1980-05-02 IT IT21723/80A patent/IT1131109B/it active
- 1980-05-02 BE BE0/200456A patent/BE883096A/fr not_active IP Right Cessation
- 1980-05-02 CA CA000351182A patent/CA1157375A/fr not_active Expired
- 1980-05-05 WO PCT/FR1980/000069 patent/WO1980002426A1/fr active Application Filing
- 1980-05-05 NL NL8020152A patent/NL8020152A/nl active Search and Examination
- 1980-05-05 GB GB8040646A patent/GB2061287B/en not_active Expired
- 1980-05-05 AR AR280901A patent/AR227021A1/es active
- 1980-05-05 DE DE3043409T patent/DE3043409C3/de not_active Expired - Fee Related
- 1980-05-05 JP JP55500927A patent/JPH0424360B2/ja not_active Expired
- 1980-05-05 CH CH98/81A patent/CH654329A5/fr not_active IP Right Cessation
- 1980-05-05 AT AT0903980A patent/ATA903980A/de unknown
- 1980-05-06 MX MX808799U patent/MX5960E/es unknown
- 1980-12-29 SE SE8009157A patent/SE452250C/sv not_active IP Right Cessation
-
1981
- 1981-01-02 NO NO81810009A patent/NO155477C/no unknown
- 1981-01-02 DK DK001281A patent/DK157169C/da not_active IP Right Cessation
-
1983
- 1983-03-17 US US06/476,126 patent/US4465623A/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560475A (en) * | 1969-06-19 | 1971-02-02 | Baxter Laboratories Inc | Prothrombin complex prepared by precipitation with polyethylene glycol |
| DE2029455A1 (de) * | 1969-06-19 | 1971-02-25 | Baxter Laboratories Ine , Morton Grove, 111 (VStA) | Verfahren zur Herstellung eines neuen Prothrombinkomplexes |
| EP0018353A1 (de) * | 1979-04-19 | 1980-10-29 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Verfahren zur Herstellung von nebenwirkungsfreien Plasmafraktionen |
Non-Patent Citations (4)
| Title |
|---|
| Blood 1977, 49 (2), 159-70 * |
| Thromb. Diath. Haemorrh. 1972, 27(3), 490-501 * |
| Thromb. Res. 1978, 12(4), 571-82 * |
| Vox Sang. 1972, 22(2), 137-60 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DK157169C (da) | 1990-04-23 |
| ES8100763A1 (es) | 1980-12-01 |
| BE883096A (fr) | 1980-11-03 |
| WO1980002426A1 (fr) | 1980-11-13 |
| DK1281A (da) | 1981-01-02 |
| FR2472390A1 (fr) | 1981-07-03 |
| NO810009L (no) | 1981-01-02 |
| AR227021A1 (es) | 1982-09-15 |
| NO155477B (no) | 1986-12-29 |
| GB2061287B (en) | 1983-09-14 |
| NO155477C (no) | 1987-04-08 |
| MX5960E (es) | 1984-09-06 |
| DK157169B (da) | 1989-11-20 |
| SE8009157L (sv) | 1980-12-29 |
| CH654329A5 (fr) | 1986-02-14 |
| FR2472390B1 (en, 2012) | 1983-07-08 |
| US4465623A (en) | 1984-08-14 |
| CA1157375A (fr) | 1983-11-22 |
| SE452250B (sv) | 1987-11-23 |
| IT8021723A0 (it) | 1980-05-02 |
| SE452250C (sv) | 1998-04-06 |
| DE3043409C3 (de) | 1993-12-23 |
| IT1131109B (it) | 1986-06-18 |
| ATA903980A (de) | 1982-05-15 |
| DE3043409T1 (de) | 1982-02-18 |
| JPS56500569A (en, 2012) | 1981-04-30 |
| NL8020152A (nl) | 1981-02-27 |
| JPH0424360B2 (en, 2012) | 1992-04-24 |
| GB2061287A (en) | 1981-05-13 |
| ES491042A0 (es) | 1980-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3043409C2 (en, 2012) | ||
| EP0244834B1 (de) | Verfahren zur Herstellung eines Faktor V-Konzentrats | |
| AT407115B (de) | Verfahren zur herstellung eines konzentrates von standardisiertem, menschlichem von willebrand-faktor | |
| DE69213421T2 (de) | Verfahren zur Herstellung eines aktivierten Faktor VII-Konzentrates mit einer hohen Reinheit | |
| DE3686475T2 (de) | Verfahren zur herstellung des alpha-1-proteinase-inhibitors. | |
| DE69127384T2 (de) | Verfahren zur Reinigung von Immunserumglobulinen | |
| DE60207848T2 (de) | Verfahren zur herstellung von konzentrierten menschlichen immunoglobulinen für die therapeutische verwendung | |
| DE68922358T3 (de) | Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen. | |
| EP0056629B1 (de) | Verfahren zur Reinigung der Blutgerinnungsfaktoren II, VII, IX und/oder X und danach hergestellte Präparationen | |
| DE2645466C2 (de) | Verfahren zum Isolieren von Albumin aus Plasmaprodukten | |
| DE69017050T2 (de) | Verfahren zur isolierung von faktor viii. | |
| DE3686470T2 (de) | Verfahren zur herstellung des alpha-1-proteinase-inhibitors. | |
| DE2734821B2 (de) | Blutgerinnungsfördernde Präparation und Verfahren zu ihrer Herstellung | |
| DE2854381A1 (de) | Verfahren zur gewinnung des antihaemophilen faktors viii aus blut, blutplasma oder blutplasma-fraktionen | |
| EP0447585A1 (de) | Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates | |
| DD298110A5 (de) | Verfahren zur herstellung eines konzentrats des blutgerinnungsfaktor-viii-von-willebrand-faktor-komplexes aus gesamten plasma | |
| DE69221369T2 (de) | Verfahren zur Herstellung eines Konzentrates von Blutgerinnungsfaktor XI mit hoher spezifischer Aktivität zur therapeutischen Verwendung | |
| DE3751576T2 (de) | Virale Inaktivierung und Reinigung von aktiven Proteinen. | |
| DE69024105T2 (de) | Verfahren zur Herstellung von gereinigten Albuminlösungen | |
| EP0111777B1 (de) | Gerinnungsaktive Plasmaproteinlösung, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Störungen des Hämostasesystems | |
| DE3432083A1 (de) | Pasteurisierte, isoagglutininfreie faktor viii-praeparation und verfahren zu ihrer herstellung | |
| DE2532151C3 (de) | Antisenim zur quantitativen Bestimmung der Abbauprodukte des Fibrins und Fibrinogen« und Verfahren zu seiner Herstellung | |
| EP0367840B1 (de) | Verfahren zur Herstellung eines hochreinen, nicht infektiösen Antihämophiliefaktors mittels Chromatographie | |
| EP0049861B1 (de) | Thrombininhibitor, seine Herstellung und Verwendung | |
| DE2323981A1 (de) | Antikoagulansisolierung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| 8366 | Restricted maintained after opposition proceedings | ||
| 8305 | Restricted maintenance of patent after opposition | ||
| D4 | Patent maintained restricted | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: DERZEIT KEIN VERTRETER BESTELLT |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: KERN, W., DIPL.-ING. BREHM, H., DIPL.-CHEM. DR.PHIL.NAT. VOLPERT, M., DIPL.-ING. DR.-ING., PAT.-ANWAELTE, 81369 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |